Holen Sie sich die Stockscreener-App
199.23
0.10%
0.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$199.03
Offen:
$199.49
24-Stunden-Volumen:
264.57K
Relative Volume:
1.36
Marktkapitalisierung:
$3.92B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
79.37
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-0.81%
1M Leistung:
+6.73%
6M Leistung:
+94.47%
1J Leistung:
+70.94%
1-Tages-Spanne:
$198.90
$204.27
1-Wochen-Bereich:
$198.82
$210.76
52-Wochen-Spanne:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
199.23 | 3.92B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Is Ligand Pharmaceuticals Incorporated (LGDN) stock testing key supportPortfolio Return Report & Stepwise Swing Trade Plans - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock hit analyst forecastsQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
Will Ligand Pharmaceuticals Incorporated stock attract ESG investorsJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
Is Ligand Pharmaceuticals Incorporated stock positioned for long term growth2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Why Ligand Pharmaceuticals Incorporated (LGDN) stock is favored by hedge fundsPortfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Ligand Pharmaceuticals (LGND): Assessing Valuation After Strong Recent Share Price Gains - Yahoo Finance
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know - AOL.com
Is Ligand Pharmaceuticals Incorporated (LGDN) stock good for long term investingCPI Data & Weekly Setup with High ROI Potential - newser.com
Will Ligand Pharmaceuticals Incorporated (LGDN) stock outperform foreign stocks2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
How Ligand Pharmaceuticals’ Strong Q3 Results and Raised Guidance May Impact LGND Investors - Yahoo Finance
How strong is Ligand Pharmaceuticals Incorporated (LGDN) stock earnings growthMarket Performance Report & Verified Short-Term Trading Plans - newser.com
Intraday pattern recognizer results for Ligand Pharmaceuticals Incorporated - newser.com
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? - Yahoo Finance
How supply chain issues affect Ligand Pharmaceuticals Incorporated stockWeekly Gains Summary & Daily Stock Trend Watchlist - newser.com
How Ligand Pharmaceuticals Incorporated (LGDN) stock performs during market turbulenceJuly 2025 Opening Moves & Expert Verified Stock Movement Alerts - newser.com
Is Ligand Pharmaceuticals Incorporated reversing from oversold territoryPortfolio Performance Summary & Fast Entry High Yield Tips - newser.com
Virtual Meeting Set for Ligand Pharmaceuticals (LGND) on November 25 - GuruFocus
Ligand Pharmaceuticals (LGND) Price Target Increased by 24.57% to 232.69 - Nasdaq
What moving averages say about Ligand Pharmaceuticals Incorporated2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):